Bionomics begins manufacture of anti-cancer stem cell treatment

04/25/2013 | Pharmaceutical Business Review Online

Bionomics has begun production work for BNC101, its stem cell therapy candidate for cancer, at its U.K. plant in Slough. "The start of manufacturing activities for BNC101 signals a significant step towards clinical trials," said Bionomics' CEO and managing director, Dr. Deborah Rathjen. The firm expects clinical studies to start next year.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX